Basic Search
|
Geographic Searches
|
Advanced Search |
MegadealsSubsidy Tracker: Industry Summary Page
Major Industry: pharmaceuticals
Subsidy Total: $3,972,211,621
Number of Awards: 2,783
Time Period: Earliest year of data: 1975. Availability of data for earlier years varies greatly from program to program. The majority of the listings for this industry are for the period since 2012.
Notes: The dollar total above adjusts for the fact that there is an overlap between the amounts in one or more Megadeal entries and those of one or more of the other entries. The total includes only those entries matched to a parent company. The industry designation is the primary one for the parent's operations overall. Dollar totals do not include awards for which no subsidy value is disclosed.
Top 10 Parent Companies | Total Subsidy $ | Number of Awards |
Eli Lilly | $601,741,368 | 77 |
Regeneron Pharmaceuticals | $469,433,071 | 112 |
AstraZeneca | $436,175,713 | 52 |
Pfizer | $332,313,011 | 206 |
Novo Holdings A/S | $241,475,902 | 102 |
Elanco Animal Health | $189,545,200 | 7 |
Merck | $153,889,367 | 82 |
AbbVie | $145,729,008 | 68 |
Johnson & Johnson | $111,279,431 | 124 |
Bristol-Myers Squibb | $110,616,473 | 81 |
Individual Subsidy Records:
Warning: Attempt to read property "post_title" on string in
/usr/home/goodjobsfirst/public_html/subsidytrackerlive/function.php on line
2057
Warning: Attempt to read property "post_name" on string in
/usr/home/goodjobsfirst/public_html/subsidytrackerlive/function.php on line
2059
Company | Parent | Location | Subsidy Source | Year | Subsidy Value | Loan/Bailout Value | Type of Subsidy |
IMMUNE DESIGN CORP | Merck | Washington | state | 2013 | $4,304 | | tax credit/rebate |
IMMUNE DESIGN CORP | Merck | Washington | state | 2013 | $9,868 | | tax credit/rebate |
SEATTLE GENETICS INC | Seattle Genetics Inc. | Washington | state | 2013 | $13,467 | | tax credit/rebate |
SEATTLE GENETICS INC | Seattle Genetics Inc. | Washington | state | 2013 | $17,655 | | tax credit/rebate |
ONCOTHYREON INC | Seattle Genetics Inc. | Washington | state | 2013 | $19,669 | | tax credit/rebate |
GILEAD SCIENCES INC | Gilead Sciences | Washington | state | 2013 | $41,681 | | tax credit/rebate |
OMEROS CORP | Omeros Corp. | Washington | state | 2013 | $44,191 | | tax credit/rebate |
NOVO NORDISK INC | Novo Holdings A/S | Washington | state | 2013 | $48,418 | | tax credit/rebate |
EMERGENT PRODUCT DEVELOPMENT SEATTLE LLC | Emergent BioSolutions | Washington | state | 2013 | $62,739 | | tax credit/rebate |
SANOFI AVENTIS US LLC | Sanofi | Washington | state | 2013 | $70,422 | | tax credit/rebate |
ZYMOGENETICS INC | Bristol-Myers Squibb | Washington | state | 2013 | $102,839 | | tax credit/rebate |
GILEAD SCIENCES INC | Gilead Sciences | Washington | state | 2013 | $141,588 | | tax credit/rebate |
NOVO NORDISK INC | Novo Holdings A/S | Washington | state | 2013 | $298,709 | | tax credit/rebate |
NOVO NORDISK INC | Novo Holdings A/S | Washington | state | 2014 | $273,088 | | tax credit/rebate |
GILEAD SCIENCES INC | Gilead Sciences | Washington | state | 2014 | $403,872 | | tax credit/rebate |
SEATTLE GENETICS INC | Seattle Genetics Inc. | Washington | state | 2014 | $13,522 | | tax credit/rebate |
IMMUNE DESIGN CORP | Merck | Washington | state | 2014 | $22,572 | | tax credit/rebate |
EMERGENT PRODUCT DEVELOPMENT SEATTLE LLC | Emergent BioSolutions | Washington | state | 2014 | $83,367 | | tax credit/rebate |
NOVO NORDISK INC | Novo Holdings A/S | Washington | state | 2014 | $48,418 | | tax credit/rebate |
OMEROS CORP | Omeros Corp. | Washington | state | 2014 | $398,897 | | tax credit/rebate |
GILEAD SCIENCES INC | Gilead Sciences | Washington | state | 2014 | $41,681 | | tax credit/rebate |
SEATTLE GENETICS INC | Seattle Genetics Inc. | Washington | state | 2014 | $185,655 | | tax credit/rebate |
ONCOTHYREON INC | Seattle Genetics Inc. | Washington | state | 2014 | $19,669 | | tax credit/rebate |
IMMUNE DESIGN CORP | Merck | Washington | state | 2014 | $10,326 | | tax credit/rebate |
ZYMOGENETICS INC | Bristol-Myers Squibb | Washington | state | 2014 | $102,925 | | tax credit/rebate |
EMERGENT PRODUCT DEVELOPMENT SEATTLE LLC | Emergent BioSolutions | Washington | state | 2014 | $83,218 | | tax credit/rebate |
SANOFI AVENTIS US LLC | Sanofi | Washington | state | 2014 | $70,422 | | tax credit/rebate |
SANOFI-AVENTIS US LLC | Sanofi | Washington | state | 2015 | $70,422 | | tax credit/rebate |
OMEROS CORPORATION | Omeros Corp. | Washington | state | 2015 | $398,897 | | tax credit/rebate |
ZYMOGENETICS INC | Bristol-Myers Squibb | Washington | state | 2015 | $102,925 | | tax credit/rebate |
NOVO NORDISK INC | Novo Holdings A/S | Washington | state | 2015 | $48,418 | | tax credit/rebate |
GILEAD SCIENCES INC | Gilead Sciences | Washington | state | 2015 | $41,681 | | tax credit/rebate |
CASCADIAN THERAPEUTICS INC | Seattle Genetics Inc. | Washington | state | 2015 | $19,669 | | tax credit/rebate |
SEATTLE GENETICS INC | Seattle Genetics Inc. | Washington | state | 2015 | $13,467 | | tax credit/rebate |
IMMUNE DESIGN CORP | Merck | Washington | state | 2015 | $10,326 | | tax credit/rebate |
SANOFI-AVENTIS US LLC | Sanofi | Washington | state | 2016 | $70,422 | | tax credit/rebate |
CASCADIAN THERAPEUTICS INC | Seattle Genetics Inc. | Washington | state | 2016 | $19,669 | | tax credit/rebate |
GILEAD SCIENCES INC | Gilead Sciences | Washington | state | 2016 | $41,681 | | tax credit/rebate |
IMMUNE DESIGN CORP | Merck | Washington | state | 2016 | $10,326 | | tax credit/rebate |
NOVO NORDISK INC | Novo Holdings A/S | Washington | state | 2016 | $273,143 | | tax credit/rebate |
OMEROS CORPORATION | Omeros Corp. | Washington | state | 2016 | $309,936 | | tax credit/rebate |
SEATTLE GENETICS INC | Seattle Genetics Inc. | Washington | state | 2016 | $189,472 | | tax credit/rebate |
ZYMOGENETICS INC | Bristol-Myers Squibb | Washington | state | 2016 | $102,839 | | tax credit/rebate |
ZYMOGENETICS, INC. | Bristol-Myers Squibb | Washington | state | 2017 | $5,971,568 | | tax credit/rebate |
OMEROS CORPORATION | Omeros Corp. | Washington | state | 2017 | $2,436,956 | | tax credit/rebate |
NOVO NORDISK RESEARCH CENTER SEATTLE, INC. | Novo Holdings A/S | Washington | state | 2017 | $2,185,140 | | tax credit/rebate |
SEATTLE GENETICS, INC. | Seattle Genetics Inc. | Washington | state | 2017 | $1,515,773 | | tax credit/rebate |
GILEAD SCIENCES, INC. | Gilead Sciences | Washington | state | 2017 | $333,444 | | tax credit/rebate |
CASCADIAN THERAPEUTICS, INC. | Seattle Genetics Inc. | Washington | state | 2017 | $157,351 | | tax credit/rebate |
IMMUNE DESIGN CORP. | Merck | Washington | state | 2017 | $115,926 | | tax credit/rebate |
NOVO NORDISK RESEARCH CENTER SEATTLE, INC. | Novo Holdings A/S | Washington | state | 2018 | $8,135,140 | | tax credit/rebate |
NOVO NORDISK RESEARCH CENTER SEATTLE, INC. | Novo Holdings A/S | Washington | state | 2019 | $7,847,528 | | tax credit/rebate |
OMEROS CORPORATION | Omeros Corp. | Washington | state | 2018 | $2,479,491 | | tax credit/rebate |
OMEROS CORPORATION | Omeros Corp. | Washington | state | 2019 | $2,138,039 | | tax credit/rebate |
GILEAD SCIENCES, INC. | Gilead Sciences | Washington | state | 2018 | $333,444 | | tax credit/rebate |
IMMUNE DESIGN CORP. | Merck | Washington | state | 2018 | $115,926 | | tax credit/rebate |
Novo Nordisk Research Center Seattle, Inc. | Novo Holdings A/S | Washington | state | 2020 | $4,725,452 | | tax credit/rebate |
Novo Nordisk Research Center Seattle, Inc. | Novo Holdings A/S | Washington | state | 2021 | $4,725,452 | | tax credit/rebate |
Omeros Corporation | Omeros Corp. | Washington | state | 2020 | $2,125,967 | | tax credit/rebate |
Omeros Corporation | Omeros Corp. | Washington | state | 2021 | $2,125,967 | | tax credit/rebate |
Novo Nordisk Research Center Seattle, Inc. | Novo Holdings A/S | Washington | state | 2022 | $2,645,382 | | tax credit/rebate |
Barr Laboratories, Inc. | Teva Pharmaceutical Industries | Virginia | state | 2008 | $400,000 | | grant |
Wyeth Pharmaceuticals | Pfizer | Virginia | state | 2004 | $2,000,000 | | grant |
Merck | Merck | Virginia | state | 2007 | $1,500,000 | | grant |
Barr Laboratories Inc. | Teva Pharmaceutical Industries | Virginia | state | 2008 | $500,000 | | grant |
Merck & Co., Inc. | Merck | Virginia | state | 2010 | $89,383 | | training reimbursement |
Novozymes Biologicals, Inc. | Novo Holdings A/S | Virginia | state | 2010 | $44,312 | | training reimbursement |
Merck Sharpe & Dohme | Merck | Virginia | state | 2016 | $1,300,000 | | grant |
Abbott Laboratories | Abbott Laboratories | Virginia | state | 2016 | $240,000 | | grant |
Abbott Laboratories | Abbott Laboratories | Virginia | state | 2016 | $300,000 | | grant |
Merck & Co | Merck | Virginia | state | 2016 | $1,300,000 | | grant |
Merck (2015) | Merck | Virginia | state | 2016 | $450,000 | | training reimbursement |
Merck (2015) | Merck | Virginia | state | 2017 | $450,000 | | training reimbursement |
Abbott Laboratories Retrain | Abbott Laboratories | Virginia | state | 2017 | $65,639 | | training reimbursement |
Abbott Laboratories. | Abbott Laboratories | Virginia | state | 2017 | $34,078 | | training reimbursement |
Merck & Co., Inc. | Merck | Virginia | state | 2019 | $7,500,000 | | grant |
Bausch & Lomb | Bausch Health | Virginia | state | 2023 | $300,000 | | grant |
Abbott Laboratories | Abbott Laboratories | Virginia | state | 2020 | $300,000 | | grant |
Merck | Merck | Virginia | state | 2019 | $1,300,000 | | grant |
Merck | Merck | Virginia | state | 2015 | $1,500,000 | | grant |
Merck | Merck | Virginia | state | 2007 | $500,000 | | grant |
Bausch & Lomb | Bausch Health | Virginia | state | 2020 | $210,000 | | grant |
Mylan Technologies, Inc. | Viatris | Vermont | state | 1999 | $576,729 | | tax credit/rebate; property tax abatement |
Mylan Technologies, Inc. | Viatris | Vermont | state | 2003 | $2,426,152 | | tax credit/rebate; property tax abatement |
PBM Nutritionals, LLC | Perrigo | Vermont | state | 2004 | $2,755,595 | | tax credit/rebate; property tax abatement |
PBM Nutritionals | Perrigo | Vermont | state | 2010 | $96,617 | | training reimbursement |
Mylan Technologies, Inc. | Viatris | Vermont | state | 2010 | $50,200 | | training reimbursement |
Mylan Technologies, Inc | Viatris | Vermont | state | 2012 | $4,228,373 | | grant |
Mylan Technologies | Viatris | Vermont | state | 2011 | $41,813 | | training reimbursement |
MYLAN TECHNOLOGIES | Viatris | Vermont | state | 2014 | $206,180 | | training reimbursement |
PBM Nutritionals | Perrigo | Vermont | state | 2012 | $144,711 | | training reimbursement |
Cephalon | Teva Pharmaceutical Industries | Utah | state | 2009 | $1,683,200 | | tax credit/rebate |
Megadyne Medical Products | Johnson & Johnson | Utah | state | 2009 | $8,538 | | training reimbursement |
Watson Laboratories, Inc. | Teva Pharmaceutical Industries | Utah | state | 2009 | $7,450 | | training reimbursement |
Millipore Corporation | Merck KGaA (EMD) | United States | federal | 2009 | $608,447 | | federal grant |
EMD Serono Research Center, Inc. | Merck KGaA (EMD) | United States | federal | 2011 | $31,419 | | federal grant |
AstraZeneca Pharmaceuticals LP | AstraZeneca | United States | federal | 2012 | $2,713,491 | | federal grant |
GlaxoSmithKline | GlaxoSmithKline | United States | federal | 2012 | $4,011,709 | | federal grant |
HI TECH Pharmacal Company | Akorn Inc. | United States | federal | 2012 | $603,688 | | federal grant |
GlaxoSmithKline | GlaxoSmithKline | United States | federal | 2012 | $729,692 | | federal grant |
Morphotek, Inc. | Eisai | United States | federal | 2012 | $141,901 | | federal grant |